Table 1.

Patient Course and Management After Disease Progression

Patient	Response	Site(s) of Progression	Treatment(s) and duration (years) after Vandetanib	Time after Stopping Vandetanib (years)
3	PD	Non-target- cervical spine lesion*	None	0.4#
7	SD -> PD	Non-target– groin	Cabozantinib (0.44), Sunitinib (0.8), Sorafenib (1.35)	3.1#
8		Previously unidentified–prostate*	Cabozantinib (0.79)	1.1#
9		Target- neck	Neck Dissection/Debulking (5.14)	5.9
17		Elevation in CEA/Calcitonin	Cabozantinib (3.21)	4.1
1	PR -> PD	Target - liver	Cabozantinib (1.34), Sunitinib (2.33)	4.1#
4		Non-target– mediastinum	Sorafenib (0.15), Cabozantinib (0.22), Cabozantinib (0.61), Sunitinib (1.07)	3.1#
6		Target- neck, chest	None	1.73
12		Target- mediastinum	None	0ϕ
14		Non-target– neck*	Sunitinib (0.13), Cabozantinib (0.15)	0.7#

Progressive Disease (PD), Stable Disease (SD), Partial Response (PR), Carcinoembryonic Antigen (CEA)

^*Present on baseline imaging,

^#Death from Disease,

^ϕStill taking vandetanib at data cutoff